SCA
BBIO icon

Snowden Capital Advisors’s BridgeBio Pharma BBIO Stock Holding History

Snowden Capital Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Buy
+3,471
New +$243K 0.01% 1156
2022
Q1 		– Sell
-19
Closed – – 1128
2021
Q4 		$0 Buy
+19
New +$804 ﹤0.01% 2047

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Snowden Capital Advisors's BBIO Position: Q2 2026 in Review

Snowden Capital Advisors opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 3,471 shares worth $259K. The stake represents 0.01% of the portfolio and ranks #1156 among its holdings. This is a return to the name: Snowden Capital Advisors previously reported a position in BBIO as recently as Q4 2021.

Snowden Capital Advisors first reported a position in BBIO in Q4 2021 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Snowden Capital Advisors held 3,471 shares of BridgeBio Pharma worth $259K as of Q2 2026.
  • BridgeBio Pharma was a new Snowden Capital Advisors position in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1156 holding.
  • Snowden Capital Advisors first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.